A NEW APPROACH TO THE INHIBITION OF PUERPERAL LACTATION

Publisher Website
Google Scholar
Abstract
Summary: Inhibition of lactation by the new peptide ergot alkaloid 2‐Br‐α‐ergocryptine (CB154) was studied in a double‐blind trial. Forty patients divided into four groups were treated during seven consecutive days with daily doses of either 2.5 mg., 5.0 mg., 7–5 mg. of CB154 or a placebo. In terms of milk secretion, engorgement and pain the CB154 therapy was significantly better than the placebo. Tolerance of CB154 was good and no drug‐related side effects were observed. In a further trial CB154 was tried in five patients with already established lactation and in 22 patients who had not responded to standard hormonal therapy. With one exception (suppression of lactation after four months of full breast‐feeding) excellent results were achieved.For prevention as well as for the suppression of already established lactation, the following dosage schedule of CB154 is effective and avoids a rebound phenomenon: 2.5 mg. twice daily for two weeks, followed by 2.5 mg. once daily for one week.